Since there is limited data in breast and ovarian cancer, studies conducted in other tumor cell models suggest the combination of HDAC inhibitors and DNA-targeted agents is a rational therapeutic approach in the treatment of OC. This evidence concerns the gene HDAC9 and neoplasm.